制度・支援
指定難病 — No.100

巨大膀胱短小結腸腸管蠕動不全症

検索語 Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome ・ 最終更新 2026-09-17 15:51 ・ 最新に更新

Data Sheet
指定 No.100
Src PubMed · CT.gov · jRCT

これは医療アドバイスではありません。診断・治療の判断は必ず主治医にご相談ください。論文や治験は「今わかっている研究の状況」を示すもので、効果を保証するものではありません。

( 01 )EVIDENCE / PUBMED · 5件

世界の論文

直近の研究を、やさしい日本語で

各論文の見出しにある「確からしさ」は、その研究がどれくらい信頼できるかの目安です。「理論段階」はまだ仮説に近く、下にいくほど多くの患者で検証されていて、「メタ解析」がもっとも信頼できます。

症例報告
MK-01 · PMID 42564772

Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) due to a de novo ACTG2 mutation: A neonatal case report

Abstract / 原文

BACKGROUND: Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) is a rare congenital visceral myopathy characterized by severe gastrointestinal dysmotility and bladder dysfunction, most commonly associated with ACTG2-mutations. CASE REPORT: We report a preterm neonate with prenatally detected megacystis and a de novo heterozygous ACTG2 variant (c.593G>T; p.Gly198Val). Postnatally, the patient developed progressive abdominal distension and feeding intolerance. Imaging demonstrated dilated bowel loops and microcolon. Exploratory laparotomy on day 5 confirmed dilated ileum, microcolon, and massive megacystis without mechanical obstruction. Gastrostomy and ileostomy were performed. The patient required parenteral nutrition followed by gradual enteral feeding with stool recirculation. Clean intermittent catheterization and antibiotic prophylaxis were initiated. CONCLUSION: MMIHS should be suspected in cases of fetal megacystis. Early genetic diagnosis and multidisciplinary management, including intestinal failure rehabilitation and urological care, are essential to improve outcomes.

Journal
Intestinal Failure (New York, N.Y.)(2026)
Authors
5名
Type
Case Reports, Journal Article
PubMedで原文を見る
基礎研究(細胞・動物など)
MK-02 · PMID 42063440

Case Report: Diagnostic odyssey in rare diseases: when genetic variants are misinterpreted

Abstract / 原文

INTRODUCTION: The diagnostic odyssey in rare diseases often involves the misinterpretation of genetic data, particularly when multidisciplinary approaches are lacking. This study illustrates the critical process of interpreting variants from next-generation sequencing (NGS) through a real-life case of a child misdiagnosed with Marfan Syndrome (MFS). The misdiagnosis was maintained for over seven years despite repeated clinical evaluations by different specialists. An initial clinical suspicion of MFS due to joint hypermobility at 3 years of age became a definitive diagnosis after an external laboratory reported a heterozygous variant in the MYH11 gene at age 5, despite the patient never fulfilling the established clinical diagnostic criteria for the disease. METHODS: To provide an accurate diagnosis and end the family's diagnostic odyssey, a complete clinical and genetic reinterpretation was performed when the patient was 7 years old. The proband and 9 asymptomatic relatives were recruited for a functional study of the MYH11 c.5544_5548del, p.(D1848Efs*60) variant. RESULTS: The functional analysis demonstrated that the variant operates through a loss-of-function mechanism, leading to nonsense-mediated mRNA decay. While gain-of-function variants in MYH11 are associated with thoracic aortic aneurysms and dissections, loss-of-function variants are linked to autosomal recessive Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome (MMIHS). As a heterozygous carrier of a loss-of-function variant, the patient is asymptomatic for MMIHS and definitively does not have MFS. Currently, the 11-year-old child is progressing favorably without any notable pathology. CONCLUSIONS: This case exposes the entire diagnostic odyssey suffered by the patient's family and highlights three fundamental systemic errors: the critical delay in genetic counseling, the over-interpretation of NGS data by external laboratories lacking phenotypic context, and the health system's inefficiency in integrating clinical geneticists. Overcoming these barriers is essential for the true implementation of personalized precision medicine.

Journal
Frontiers in pediatrics(2026)
Authors
5名
Type
Journal Article
PubMedで原文を見る
基礎研究(細胞・動物など)
MK-03 · PMID 41797110

Myh11 haploinsufficiency recapitulates megacystis and voiding dysfunction in a mouse model of MMIHS

Abstract / 原文

BACKGROUND: Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) is a fatal rare disorder characterized by bladder and colonic smooth muscle dysfunction. Mutations in the MYH11 gene have been identified as one of the causative factors of MMIHS. OBJECTIVE: This study aimed to generate a Myh11 knockout mouse model, evaluate the phenotypes and function of the bladder and intestines, and investigate the association between Myh11 deficiency and the core clinical features of MMIHS. STUDY DESIGN: Gene expression was assessed by qRT-PCR and Western blot. Protein localization and expression were determined using immunohistochemistry. Histomorphological changes were evaluated through hematoxylin-eosin (H&E) and Masson staining. Bladder function was analyzed via void spot assay and post-void residual volume measurements, while smooth muscle contractility was measured using muscle tension assays. Intestinal motility was assessed using established gastrointestinal transit tests, and cell proliferation was examined by BrdU incorporation assay. RESULTS: Compared with wildtype mice, Myh11+/- heterozygote mice showed significantly reduced Myh11 expression at both mRNA and protein levels in bladder tissues (P < 0.001). Immunohistochemical staining revealed that Myh11 was predominantly expressed in the bladder smooth muscle, and a significant reduction in its expression level was observed in the bladders of Myh11+/- mice (P < 0.01). Phenotypically, Myh11+/- mice exhibited a markedly enlarged bladder volume (P < 0.05), an increased bladder-to-body weight ratio (P < 0.01), a thickened smooth muscle layer (P < 0.01), and enhanced collagen deposition (P < 0.01). Functionally, Myh11+/- mice displayed reduced urinary frequency and total urine output (P < 0.05), an increased residual urine volume (P < 0.001), a slowed bladder contraction (P < 0.01), along with mild intestinal dysmotility (prolonged time to first black stool, P < 0.05) and an elevated fecal water content (P < 0.05). At the molecular level, the up-regulation of PCNA protein expression and the increased incorporation of BrdU suggests active cell proliferation (P < 0.05). DISCUSSION: Myh11+/- mice successfully recapitulate the core bladder phenotypes of MMIHS, including megacystis and voiding dysfunction. This confirms the critical role of Myh11 in both the development and contractile function of the bladder, thereby providing a reliable in vivo model for in-depth investigation into the pathological mechanisms underlying bladder dysfunction in MMIHS. CONCLUSION: Myh11 deficiency leads to significant bladder enlargement, smooth muscle thickening, collagen accumulation, and voiding dysfunction, establishing a good disease model for MMIHS.

Journal
Journal of pediatric urology(2026 Jun)
Authors
8名
Type
Journal Article
PubMedで原文を見る
観察研究
MK-04 · PMID 41591435

Imaging of megacystis-microcolon-intestinal hypoperistalsis syndrome before, during, and after the neonatal period: a pictorial review

Abstract / 原文

Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), also known as Berdon syndrome, is a rare genetic congenital disorder of impaired smooth muscle contractility, resulting in functional obstruction of the bladder and bowel. Historically associated with a poor prognosis, recent advances in the use of total parenteral nutrition (TPN), intestinal rehabilitation, and multi-visceral transplantation have led to improvements in survival in patients with MMIHS, with patients now living into the second decade of life. The radiologist plays a key role in the initial workup of these patients and is often the first to suggest the diagnosis. Furthermore, with patients living longer, the radiologist's role now includes the following: (1) identifying complications on follow-up imaging, such as distinguishing mechanical obstruction from dysmotility; (2) following findings of chronic kidney disease; and (3) recognizing cholestatic TPN-related liver disease. With expedient diagnosis and management, survival can be extended, and quality of life can be improved. This pictorial essay aims to demonstrate the spectrum of imaging findings in the prenatal stage, the neonatal period, and later childhood in confirmed cases. Clinical findings, management, and outcomes of MMIHS, as well as imaging features that differentiate MMIHS from similar conditions, will be discussed.

Journal
Pediatric radiology(2026 Apr)
Authors
9名
Type
Journal Article, Review
PubMedで原文を見る
症例報告
MK-05 · PMID 41416657

Megacystis-Megacolon-Intestinal Hypoperistalsis Syndrome with Intestinal Neuronal Dysplasia: Expanding the Phenotypic Spectrum

Abstract / 原文

BACKGROUND: Megacystitis-megacolon-intestinal hypoperistalsis syndrome is a phenotypic variant of visceral neuromuscular dysfunction. Megacystitis-microcolon-intestinal hypoperistalsis syndrome is a recognized entity. However, presentation with megacolon is rarely reported, with only one case documented in association with intestinal neuronal dysplasia (IND) and malrotation. CASE REPORT: We report such a case of Megacystitis-megacolon-intestinal hypoperistalsis coexisting with IND type B and atypical malrotation in a 2-year-old male, presented with intestinal obstruction. Despite multiple surgical interventions, the patient remained TPN-dependent and eventually succumbed to sepsis. Histopathology evaluation revealed hyperganglionosis, including the presence of immature and giant ganglion cells, which supported the diagnosis of IND type B, alongside the features of visceral myopathy. CONCLUSION: This case highlights the diagnostic and therapeutic complexity posed by overlapping features of megacolon and MMIHS, especially when hyperganglionosis was present. Our case highlights the need for clinico-pathological correlation and genetic analysis in diagnosing complex pediatric motility disorders.

Journal
Fetal and pediatric pathology(2026)
Authors
4名
Type
Journal Article, Case Reports
PubMedで原文を見る
( 02 )TRIALS / JAPAN · 0件

日本で参加できる治験

現在 募集中のもの

日本で現在募集中の治験は見つかりませんでした。下の公式レジストリで条件を変えると見つかる場合があります。
( 03 )REGISTRY / jRCT

治験をもっと探す

日本の公式レジストリで全件を確認

上の一覧は ClinicalTrials.gov の一部です。日本国内の治験の多くは、日本の公式レジストリ jRCT にのみ登録されています。下記から最新の全件を確認できます。

jRCT で検索日本の臨床研究実施計画 公開システム「対象疾患名」に 巨大膀胱短小結腸腸管蠕動不全症 を入力し、「募集状況」で 募集中 にチェックして検索します。ClinicalTrials.gov で全件を見る世界最大の治験データベース(英語)「巨大膀胱短小結腸腸管蠕動不全症・日本・募集中」の条件で一覧が開きます。

※ jRCTは自動の大量データ取得を禁じているため、本サービスは自動収集せず、ご自身が公式サイトで検索できるリンクでご案内しています(規約順守)。

お金・介護・制度巨大膀胱短小結腸腸管蠕動不全症の療養に使えるかもしれない公的サポートを調べる医療費・生活費・介護の支援制度と相談先を、あなたの状況に合わせてご案内(回答は端末内で完結)
( 04 )SUPPORT

患者会・相談窓口

一人で抱え込まないでください

同じ病気の患者・家族とつながる、制度や生活の相談をする、といったときの窓口です。

全国の相談先

※ お住まいの都道府県の「難病相談支援センター」でも、医療費助成や療養生活の相談ができます(難病情報センターから探せます)。